Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OGT 2115 is an inhibitor of heparanase (IC50 = 0.4 µM), an enzyme that cleaves heparan sulfate into glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). OGT 2115 also showed antiangiogenic properties (IC50=1 μM).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,000 | |||
5 mg | 在庫あり | ¥ 16,000 | |||
10 mg | 在庫あり | ¥ 29,000 | |||
25 mg | 在庫あり | ¥ 62,500 | |||
50 mg | 在庫あり | ¥ 104,500 | |||
100 mg | 在庫あり | ¥ 154,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 18,000 |
説明 | OGT 2115 is an inhibitor of heparanase (IC50 = 0.4 µM), an enzyme that cleaves heparan sulfate into glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). OGT 2115 also showed antiangiogenic properties (IC50=1 μM). |
ターゲット&IC50 | Heparanase:0.4 μM |
In vitro | OGT 2115 obviously inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results display that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin. Heparanase InhibitorOGT 2115 can inhibit metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. The number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115, compared with the control group [2]. |
In vivo | OGT 2115 displays a plasma concentration of ~10x the heparanase IC50 following oral dosing at 20 mg/kg when administered to mice[1]. |
分子量 | 495.3 |
分子式 | C24H16BrFN2O4 |
CAS No. | 853929-59-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10.2 mg/mL (20.6 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
OGT 2115 853929-59-6 Others OGT2115 OGT-2115 Inhibitor inhibitor inhibit